About Kyorin Group
We are improving the competitiveness of our pharmaceuticals business by strengthening the domestic sales organization of Kyorin Pharmaceutical and building long-term relationships with customers. In addition, we are focusing on extending the growth curves of our core pharmaceuticals by using a lifecycle management program to develop of additional drug indications and formulations. We are also actively pursuing our FC3 strategy in respiratory medicine, otolaryngology and urology, and continue to use alliances to strengthen our lineups in those areas through the introduction of new products. The merger of Nisshin Kyorin pharmaceutical with Kyorin Pharmaceutical on October 1, 2008, will create synergies that will strengthen our R&D and sales capabilities.
